Brightgene Bio Medical Stock Return On Asset
| 688166 Stock | 30.92 1.21 4.07% |
BrightGene Bio Medical fundamentals help investors to digest information that contributes to BrightGene Bio's financial success or failures. It also enables traders to predict the movement of BrightGene Stock. The fundamental analysis module provides a way to measure BrightGene Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BrightGene Bio stock.
BrightGene | Return On Asset |
BrightGene Bio Medical Company Return On Asset Analysis
BrightGene Bio's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current BrightGene Bio Return On Asset | 0.0227 |
Most of BrightGene Bio's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BrightGene Bio Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
BrightGene Total Assets
Total Assets |
|
Based on the latest financial disclosure, BrightGene Bio Medical has a Return On Asset of 0.0227. This is 100.26% lower than that of the Biotechnology sector and 100.1% lower than that of the Health Care industry. The return on asset for all China stocks is 116.21% lower than that of the firm.
BrightGene Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BrightGene Bio's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BrightGene Bio could also be used in its relative valuation, which is a method of valuing BrightGene Bio by comparing valuation metrics of similar companies.BrightGene Bio is currently under evaluation in return on asset category among its peers.
BrightGene Fundamentals
| Return On Equity | 0.06 | ||||
| Return On Asset | 0.0227 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 14.72 B | ||||
| Shares Outstanding | 422.47 M | ||||
| Shares Owned By Insiders | 39.34 % | ||||
| Shares Owned By Institutions | 18.13 % | ||||
| Price To Book | 5.55 X | ||||
| Price To Sales | 10.52 X | ||||
| Revenue | 1.18 B | ||||
| Gross Profit | 670.14 M | ||||
| EBITDA | 264.6 M | ||||
| Net Income | 200.58 M | ||||
| Total Debt | 156.87 M | ||||
| Book Value Per Share | 5.57 X | ||||
| Cash Flow From Operations | 194.77 M | ||||
| Earnings Per Share | 0.45 X | ||||
| Target Price | 44.21 | ||||
| Number Of Employees | 1.16 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 13.06 B | ||||
| Total Asset | 5.03 B | ||||
| Retained Earnings | 830.44 M | ||||
| Working Capital | 917.49 M | ||||
| Net Asset | 5.03 B | ||||
| Last Dividend Paid | 0.096 |
About BrightGene Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BrightGene Bio Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BrightGene Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BrightGene Bio Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BrightGene Stock
BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.